BioCentury | Mar 8, 2019
Company News

Merck partners with King’s College to develop non-opioid pain therapies

Merck has partnered with King's College London to translate research elucidating HCN2 as a pain target to develop non-opioid treatments for chronic neuropathic pain. The deal builds on work from the lab of Peter McNaughton...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting HCN2 could help treat pain in diabetic neuropathy. In a mouse model of diabetic neuropathy, the HCN channel inhibitor Corlanor ivabradine or nociceptive neuron-specific knockout of HCN2 decreased mechanical...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jun 27, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on LINC00477 and HCN4 could help predict the risk of atrial fibrillation. Genome-wide association studies in a total of 53,174 individuals of European ancestry identified associations between low heart rate variability and...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2) Mouse studies suggest increasing hyperpolarization-activated current in dopaminergic neurons in the brain's ventral tegmental area (VTA)...
BioCentury | Sep 15, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2) Mouse studies suggest inhibiting HCN2 could help treat inflammatory and neuropathic pain. In mice, a nonspecific...
BioCentury | Feb 23, 2009
Clinical News

Controlled release nitazoxanide: Phase II data

Data from the double-blind, placebo-controlled Phase III OPTIMA HCN-2 trial in 41 treatment-naïve patients with chronic HCV genotype 4 showed that twice-daily 675 and 1,350 mg controlled release nitazoxanide produced RVR rates of 59% and...
BioCentury | Feb 23, 2009
Clinical News

Controlled release nitazoxanide: Phase I data

In the double-blind, crossover Phase I OPTIMA HCN-1 trial in 12 healthy volunteers, twice-daily 675 and 1,350 mg controlled release nitazoxanide produced trough plasma concentrations of tizoxanide, the active metabolite of nitazoxanide, that were 3...
Items per page:
1 - 8 of 8